Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad5 CEA vaccine in CEA-expressing malignancies
NCT01147965Phase 2Completed
- Sponsor
- ImmunityBio, Inc.
- Start
- Jul 2010
- Primary completion
- May 2017
- Modality
- Gene Editing, Gene Silencing, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ETBX-011 in colorectal cancer (CRC), lung cancer, breast cancer and 2 more (6 cohorts), sponsored by ImmunityBio, Inc. Primary endpoints: Dose Limiting Toxicities at 9 weeks and Adverse Events up to 330 days. Started Jul 2010; status: completed.
02
Drugs
ETBX-011
03
Conditions
colorectal cancer (CRC)lung cancerbreast cancerprostate cancer (PCa)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT01147965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01147965.